Adjuvant chemotherapy for gastric cancer
DOI:
https://doi.org/10.14739/2310-1210.2015.6.56306Keywords:
Gastric Cancer, Adjuvant Chemotherapy, Randomized Study, Meta-analysisAbstract
Gastric cancer remains one of the most interesting problem of the oncology. Combined approach is recommended for treatment of gastric cancer patients and it use almost in all countries of the world. The role of adjuvant chemotherapy for patients with gastric cancer discusses since the mid of XX century.
Aim. This critical review consider the basic clinical research on this issue. It was found that the results of studies from theUSand European countries differ significantly from the results obtained in the works from Japan and Korea. According to clinical studies, adjuvant chemotherapy has demonstrated its efficacy only in patients 'eastern' population with a D2 lymph node dissection. At the same time, this chemotherapy regimen was not effective in patients of 'Western' populations. In this case, most of the works from the US and Europe had limited volume of lymph node dissection.
Conclusion. It is very important to start new investigations for studying the role of adjuvant chemotherapy for patients from «west» region after radical operation with D2 lymph node dissection.
References
Bondar′, G. V., Sidyuk, A. V., Lisovskaya, N. Yu., Popovich, Yu. A., Khomutov, E. V., & Stashkevich, M. A. (2012). Aktual′nye voprosy khimioterapii raka zheludka [Topical issues of chemotherapy for gastric cancer]. Mezhdunarodnyj medicinskij zhurnal, 1, 79–83. [in Ukrainian].
Gorbunova, V. A.. Besova, N. S., & Breder, V. V. (2011). Lekarstvennoye lecheniye raka zheludka i kolorektal′nogo raka [Drug treatment of gastric cancer and colorectal cancer]. Moscow: Literra [in Russian].
Krook, J. E., O'Connell, M. J., Wieand, H. S., Beart, R. W. Jr, Leigh, J. E., Kugler, J. W., et al. (1991). A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer, 67(10), 2454–2458.
Coombes, R. C., Schein, P. S., Chilvers, C. E., Wils, J., Beretta, G., Bliss, J. M., et al. (1990). A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J Clin Oncol., 8(8), 1362–1369.
Tsavaris, N., Tentas, K., Kosmidis, P., Mylonakis, N., Sakelaropoulos, N., Kosmas, C., et al. (1996) A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer. Chemotherapy, 42(3), 220–226. doi: 10.1159/000239446.
Chou, F. F., Sheen-Chen, S. M., Liu, P. P., & Chen, F. C. (1994) Adjuvant chemotherapy for resectable gastric cancer: a preliminary report. J Surg Oncol., 57(4), 239–242. doi: 10.1002/jso.2930570407.
Liu, T. S., Wang, Y., Chen, S. Y., & Sun, Y. H. (2008) An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer. EJSO, 34, 1208–1216. doi: 10.1016/j.ejso.2008.02.002.
Bang, Y. J., Kim, Y. W., Yang, H. K., Chung, H. C., Park, Y. K., Lee, K. H., et al. (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet, 379, 315–321. doi: 10.1016/S0140-6736(11)61873-4.
Sung, H. N., Park, S. R., & Yang, H-K. (2013). Adjuvant capecitabine and oxaliplatin (XELOX) for gastric cancer after D2 gastrectomy: final results from the classic trial. Annals of oncology, 24(4), 11.
Sakuramoto, S., Sasako, M., Yamaguchi, T., Kinoshita, T., Fujii, M., Nashimoto, A., et al. (2007). Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med., 357, 1810–1820. doi: 10.1056/NEJMoa072252.
Di Costanzo, F, Gasperoni, S., Manzione, L., Bisagni, G., Labianca, R., Bravi, S., et al. (2008). Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC. J Natl Cancer Inst., 100(6), 388–398. doi: 10.1093/jnci/djn054.
De Vita, F., Giuliani, F., Orditura, M., Maiello, E., Galizia, G., Di Martino, N., et al. (2007) Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Annals of Oncology, 18, 1354–1358.
Bouché, O., Ychou, M., Burtin, P., Bedenne, L., Ducreux, M., Lebreton, G., et al. (2005). Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Annals of Oncology, 16, 1488–1497. doi: 10.1093/annonc/mdi270.
Kulig, J., Kolodziejczyk, P., Sierzega, M., Bobrzynski, L., Jedrys, J., Popiela, T., et al. (2010) Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: a phase III randomized, multicenter, clinical trial. Oncology, 78(1), 54–61. doi: 10.1159/000292360.
Nakajima, T., Nashimoto, A., Kitamura, M., Kito, T., Iwanaga, T., Okabayashi, K., & Goto, M. (1999). Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet, 354(9175), 273–277. doi: 10.1016/S0140-6736(99)01048-X.
Macdonald, J. S., Fleming, T. R., Peterson, R. F., Berenberg, J. L., McClure, S., Chapman, R. A., et al. (1995). Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol., 2(6), 488–494. doi: 10.1007/BF02307081.
Bajetta, E., Buzzoni, R., Mariani, L., Beretta, E., Bozzetti, F., Bordogna, G., et al. (2002). Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Annals of Oncology, 13, 299–307.
Neri, B., de Leonardis, V., Romano, S., Andreoli, F., Pernice, L.M., Bruno, L., et al. (1996) Adjuvant chemotherapy after gastric resection in node-positive cancer: a multicentre randomised study. Brit. J. Cancer, 73(4), 549–552.
Paoletti, X., Oba, K., Burzykowski, T., Michiels, S., Ohashi, Y., Pignon, J.P., et al. (2010) Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer A Meta-analysis. JAMA, 303(17), 1729–1737. doi: 10.1001/jama.2010.534.
Bickenbach, K., & Strong, V.E. (2012) Comparisons of Gastric Cancer Treatments: East vs. West. J Gastric Cancer. 12(2), 55–62. doi: 10.5230/jgc.2012.12.2.55.
Expert Panel of the Chinese Ministry of Health (2012). Chinese guidelines for diagnosis and treatment of gastric cancer (2011 edition). Transl. Gastrointest. Cancer, 1, 103–114.
Lee, J. H., Kim, J. G., Jung, H. K., Kim, J. H., Jeong, W. K., Jeon, T. J., et al. (2014) Clinical Practice Guidelines for Gastric Cancer in Korea: An Evidence-Based Approach. J Gastric Cancer, 14(2), 87–104. doi: 10.5230/jgc.2014.14.2.87.
Strong, V. E., Song, K. Y., Park, C. H., Jacks, L. M., Gonen, M., Shah, M., et al. (2010) Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg., 251, 640–646. doi: 10.1097/SLA.0b013e3181d3d29b.
Diaz-Nieto, R., Orti-Rodríguez, R., & Winslet, M. (2013) Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. Cochrane Database of Systematic Reviews, 9, CD008415. doi: 10.1002/14651858.CD008415.pub2.
Popiela, T., Kulig, J., Czupryna, A., Szczepanik, A. M., & Zembala, M. (2004). Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer. Gastric Cancer, 7, 240–245. doi: 10.1007/s10120-004-0299-y.
Oba, K., Morita, S., Tsuburaya, A., Kodera, Y., Kobayashi, M., & Sakamoto, J. (2006). Efficacy of adjuvant chemotherapy using oral fluorinated pyrimidines for curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials in Japan. J Chemother., 18(3), 311–317. doi: 10.1179/joc.2006.18.3.311.
Chern, H., Chou, J., Donkor, C., Shia, J., Guillem, J. G., Nash, G. M., et al. (2010). Effects of obesity in rectal cancer surgery. J Am Coll Surg., 211, 55–60. doi: 10.1016/j.jamcollsurg.2010.03.010.
Lise, M., Nitti, D., Marchet, A., Sahmoud, T., Buyse, M., Duez, N., et al. (1995). Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol., 13(11), 2757–2763.
Sasako, M., Sakuramoto, S., Katai, H., Kinoshita, T., Furukawa, H., Yamaguchi, T., et al. (2011) Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer. J Clin Oncol., 29(33), 4387–4393. doi: 10.1200/JCO.2011.36.5908.
Ajani, J. A., Bentrem, D. J., Besh, S., D'Amico, T. A., Das, P., Denlinger, C., et al. (2013). Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw, 11(5), 531–546.
Waddell, T., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., & Arnold, D. (2014). Gastric cancer: ESMO–ESSO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Radiotherapy and Oncology, 110, 189–194.
Allum, W. H., Blazeby, J. M., Griffin, S. M., Cunningham, D., Jankowski, J. A., & Wong, R. (2011). Guidelines for the management of oesophageal and gastric cancer. Gut, 60(11), 1449–1472. doi: 10.1136/gut.2010.228254.
Tentes, A. A., Markakidis, S. K., Karanikiotis, C., Fiska, A., Tentes, I. K., Manolopoulos, V. G., & Dimitriou, T. (2006). Intraarterial chemotherapy as an adjuvant treatment in locally advanced gastric cancer. Langenbecks Arch Surg., 391(2), 124–129. doi: 10.1007/s00423-006-0022-z.
Roviello, F., Marrelli, D., de Manzoni, G., Morgagni, P., Di Leo, A., Saragoni, L., & De Stefano, A. (2003). Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg., 90(9), 1113–1119. doi: 10.1002/bjs.4164.
Noguchi, Y., Yoshikawa, T., Tsuburaya, A., Motohashi, H., Karpeh, M.S., & Brennan, M. F. (2000). Is gastric carcinoma different between Japan and the United States? Cancer, 89(11), 2237–2246. doi: 10.1002/1097-0142(20001201)89:11<2237::AID-CNCR12>3.0.CO;2-9.
Japanese Gastric Cancer Association (2011). Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer, 14, 101–112. doi: 10.1007/s10120-011-0041-5.
Bickenbach, K., & Strong, V. E. (2012). Comparisons of Gastric Cancer Treatments: East vs. West. J Gastric Cancer, 12(2), 55–62. doi: 10.5230/jgc.2012.12.2.55.
Ychou, M., Boige, V., Pignon, J.-P., Conroy, T., Bouché, O., Lebreton, G., et al. (2011) Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial. Journal of clinical oncology, 29(13), 1715–1721. doi: 10.1200/JCO.2010.33.0597.
Kulig, J., Wallner, G., Drews, M., Frączek, M., Jeziorski, A., Kielan, W., et al. (2013). Polish consensus on treatment of gastric cancer; update 2013. Pol Przegl Chir, 85(9), 544–562, doi: 10.2478/pjs-2013-0083.
Grau, J. J., Estapé, J., Alcobendas, F., Pera, C., Daniels, M., & Terés, J. (1993). Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients. Eur J Cancer, 29A(3), 340–342. doi: http://dx.doi.org/10.1016/0959-8049(93)90381-O.
Kunisaki, C., Makino, H., Takagawa, R., Sato, K., Kawamata, M., Kanazawa, A., et al. (2009). Predictive factors for surgical complications of laparoscopy-assisted distal gastrectomy for gastric cancer. Surg Endosc., 23, 2085–2093. doi: 10.1007/s00464-008-0247-8.
Miyashiro, I., Furukawa, H., Sasako, M., Yamamoto, S., Nashimoto, A., Nakajima, T., et al. (2011) Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2. Gastric Cancer, 14, 212–218. doi: 10.1007/s10120-011-0027-3.
Nitti, D., Wils, J., Dos Santos, J. G., Fountzilas, G., Conte, P. F., Sava, C., et al. (2006) Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Annals of Oncology, 17, 262–269.
Chipponi, J., Huguier, M., Pezet, D., Basso, N., Hay, J. M., Quandalle, P., et al. (2004). Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. Amer. J. Surg., 187, 440–445. doi: http://dx.doi.org/10.1016/j.amjsurg.2003.12.014.
Neri, B., Cini, G., Andreoli, F., Boffi, B., Francesconi, D., Mazzanti, R., et al. (2001) Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. British Journal of Cancer, 84(7), 878–880. doi: 10.1054/ bjoc.2001.1472.
Nakajima, T., Kinoshita, T., Nashimoto, A., Sairenji, M., Yamaguchi, T., Sakamoto, J., Fujiya, T., Inada, T., Sasako, M., Ohashi, Y. (2007). Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg., 94(12), 1468-1476.
Cirera, L., Balil, A., Batiste-Alentorn, E., Tusquets, I., Cardona, T., Arcusa, A., et al. (1999) Randomized Clinical Trial of Adjuvant Mitomycin Plus Tegafur in Patients With Resected Stage III Gastric Cancer. J Clin Oncol., 17, 3810–3815.
Nashimoto, A., Nakajima, T., Furukawa, H., Kitamura, M., Kinoshita, T., Yamamura, Y., et al. (2003). Randomized Trial of Adjuvant Chemotherapy With Mitomycin, Fluorouracil, and Cytosine Arabinoside Followed by Oral Fluorouracil in Serosa-Negative Gastric Cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol., 21, 2282–2287.
Yoo, C. H., Noh, S. H., Shin, D. W., Choi, S. H., & Min, J. S. (2000). Recurrence following curative resection for gastric carcinoma. Br J Surg., 87(2), 236–242. doi: 10.1046/j.1365-2168.2000.01360.x.
Sun, P., Xiang, J. B., & Chen, Z. Y. (2009). Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. British Journal of Surgery, 96(1), 26–33. doi: 10.1002/bjs.6408.
Hallissey, M. T., Dunn, J. A., Ward, L. C., & Allum, W. H. (1994). The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet, 343(8909), 1309–1312. doi:10.1016/S0140-6736(94)92464-3.
Zhao, S. L., & Fang, J. Y. (2008). The role of postoperative adjuvant chemotherapy following curative resection for gastric cancer: a meta-analysis. Cancer Invest., 26(3), 317–325. doi: 10.1080/07357900701834686.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
